Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.
Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.
Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.
Inspira Technologies (NASDAQ: IINN) has initiated manufacturing for the ALICE CPB device, crucial for its market strategy. This device is set for FDA 510(k) submission in 2023. The ALICE device aims to enhance CPB support in healthcare settings, equipped with a large touchscreen and real-time blood monitoring capabilities via the HYLA™ Blood Sensor. Contract manufacturing is conducted by a qualified provider meeting GMP standards. The company aims to improve patient care accessibility globally and is establishing partnerships for clinical adoption.
Inspira Technologies (NASDAQ: IINN) announced a significant agreement with Sheba Medical Center for a clinical study of its HYLA blood sensor. This study will evaluate the sensor's non-invasive capabilities for continuous blood gas measurement in patients undergoing open heart surgery. Set to commence in Q1 2023, the results aim to enhance product development. The HYLA sensor is expected to improve real-time monitoring, which could lead to better patient outcomes and reduce healthcare costs.
Inspira Technologies OXY B.H.N. Ltd. (IINN) reported financial results for Q3 2022, with cash reserves of $16.2 million. The company is focused on developing the HYLA blood sensor for cardiopulmonary bypass surgery, aiming to enhance patient monitoring.
Research and development expenses surged to $6.2 million for the nine months ending September 30, 2022, while net loss reached $7.1 million. Inspira secured strategic agreements in Europe and the U.S. for the deployment of HYLA sensors, potentially valued at $26.1 million and $59 million, respectively.
Inspira Technologies (NASDAQ: IINN) announced a 5-year exclusive distribution agreement with Innovimed for the HYLA™ Blood Sensor, designed for continuous real-time blood parameter monitoring. The agreement requires Innovimed to purchase at least 1,364 sensors and 128,511 disposable units for hospitals in Poland, Czech Republic, and Slovakia. The collaboration aims to enhance market penetration in Europe while preparing for a clinical study of the HYLA™ Blood Sensor.
Inspira Technologies (NASDAQ: IINN) announced that the Israeli Patent Office has granted a patent for a key component of its INSPIRA ART system. This component, designed to secure a neck cannula, aims to enhance patient mobility and safety during treatment, potentially reducing reliance on invasive mechanical ventilation. The company plans to seek patent protections globally and is also considering early market entry for the component in the ECMO device market, which is valued at $531 million annually.
Inspira Technologies (Nasdaq: IINN) announced its participation in the iECOs Conference happening on November 10, 2022, in Tel Aviv, Israel. The company's CTO, Daniella Yeheskely-Hayon, Ph.D., will deliver a guest lecture during the Physiology and Technology session, showcasing Inspira's innovative respiratory support technology. This technology aims to enhance patient oxygen saturation levels while minimizing the need for invasive procedures. Additionally, the scientific team will be available at their booth to provide insights and answer questions about their ongoing product developments.
Inspira Technologies (NASDAQ:IINN, IINNW) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on October 22, 2022, at 7 p.m. ET. During the interview, President Joe Hayon will discuss the Company's InspiraART System and HYLA blood sensor, highlighting significant market opportunities and their product pipeline. The InspiraART technology aims to improve patient oxygen saturation while reducing reliance on invasive mechanical ventilation. The technology is yet to be tested in humans and is pending regulatory approval.
On September 7, 2022, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced the completion of an animal study for its HYLA™ blood sensor at Lahav C.R.O. The sensor, which is non-invasive, offers real-time measurements of blood parameters, potentially improving patient monitoring and reducing risks compared to standard blood gas analyzers. The successful animal study follows earlier laboratory data and marks a significant step toward initiating human studies. This advancement is integral to Inspira's innovative respiratory support technology aimed at enhancing patient care.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that President Joe Hayon will present at the H.C. Wainwright 24th Annual Global Investor Conference on September 12, 2022, at 7:00 a.m. ET. One-on-one meetings with Hayon will take place on September 13-14, 2022. Inspira Technologies is known for its innovative Augmented Respiration Technology, aimed at improving patient oxygen saturation without invasive procedures. The technology is not yet approved for human use. For further details, visit their Investor Relations page.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q2 2022 financial results, highlighting a net loss of $3.5 million, down from $8.2 million a year earlier. Cash reserves stood at $19.2 million as of June 30, 2022. The company's R&D expenses rose to $2.7 million, driven by increased projects and share-based compensation. Inspira introduced the HYLA™ non-invasive blood sensor and revealed the ALICE™ Device for cardiopulmonary bypass, targeting respective markets of $2.5 billion and significant deployment agreements in Israel and the U.S.
